Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dexbudesonide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 7/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 9/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.72 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.72 |
| ▸ | PGR | P06401 | 4/20 | 0.72 |
| ▸ | LMNA | P02545 | 3/20 | 0.72 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.72 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.72 |
| ▸ | AR | P10275 | 2/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.72 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.72 |
| ▸ | TSHR | P16473 | 2/20 | 0.72 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.72 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.72 |
| ▸ | IL5 | P05113 | 1/20 | 0.72 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.72 |
| ▸ | MMP9 | P14780 | 1/20 | 0.72 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.72 |
| ▸ | THPO | P40225 | 1/20 | 0.72 |
| ▸ | BLM | P54132 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexbudesonide SCHEMBL8159866 | 0.93 | NR3C1 (0.78) | HSD17B10NR3C1CYP3A4HIF1APGR | |
| Dexbudesonide SCHEMBL5655286 | 0.90 | NR3C1 (0.88) | HSD17B10NR3C1CYP3A4HIF1APGR | |
| Prednisolone SCHEMBL11710056 | 0.86 | HSD17B10 (0.76) | HSD17B10NR3C1CYP3A4HIF1APGR | |
| Budesonide SCHEMBL16731476 | 0.85 | NR3C1 (1.00) | HSD17B10NR3C1CYP3A4HIF1APGR | |
| Dexbudesonide SCHEMBL4095 | 0.85 | NR3C1 (1.00) | HSD17B10NR3C1CYP3A4HIF1APGR | |
| Budesonide SCHEMBL13871728 | 0.85 | NR3C1 (1.00) | HSD17B10NR3C1CYP3A4HIF1APGR | |
| Budesonide SCHEMBL13816835 | 0.85 | NR3C1 (1.00) | HSD17B10NR3C1CYP3A4HIF1APGR | |
| Budesonide SCHEMBL13928654 | 0.85 | NR3C1 (1.00) | HSD17B10NR3C1CYP3A4HIF1APGR | |
| Budesonide SCHEMBL21570019 | 0.85 | NR3C1 (1.00) | HSD17B10NR3C1CYP3A4HIF1APGR | |
| Budesonide SCHEMBL14452945 | 0.85 | NR3C1 (1.00) | HSD17B10NR3C1CYP3A4HIF1APGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4314018-A1 | METHODS AND COMPOSITIONS FOR HIGH-POTENCY POLYPEPTIDE-BASED PROTEIN INHIBITION | Baylor College of Medicine (US) | 2024-02-07 | — | — | EP | claimed |
| US-20230210902-A1 | SARS-COV-2-SPECIFIC T CELLS | NATIONAL INSTITUTES OF HEALTH | 2023-07-06 | — | — | US | claimed |
| EP-4149496-A1 | SARS-COV-2-SPECIFIC T CELLS | Board of Regents, The University of Texas System (US) | 2023-03-22 | — | — | EP | claimed |
| WO-2022213076-A1 | METHODS AND COMPOSITIONS FOR HIGH-POTENCY POLYPEPTIDE-BASED PROTEIN INHIBITION | BAYLOR COLLEGE OF MEDICINE (US) | 2022-10-06 | — | — | WO | claimed |
| WO-2021232048-A1 | SARS-COV-2-SPECIFIC T CELLS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-11-18 | — | — | WO | claimed |
| WO-2021232050-A1 | NATURAL KILLER CELL IMMUNOTHERAPY FOR THE TREATMENT OR PREVENTION OF SARS-COV-2 INFECTION | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-11-18 | — | — | WO | claimed |
| EP-4314018-A1 | METHODS AND COMPOSITIONS FOR HIGH-POTENCY POLYPEPTIDE-BASED PROTEIN INHIBITION | Baylor College of Medicine (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-117396492-A | Methods and compositions for polypeptide-based high-efficiency protein inhibition | 贝勒医学院 | 2024-01-12 | — | — | CN | disclosed |
| US-20230372468-A1 | COMPOSITIONS AND METHODS FOR TARGETING CORONAVIRUS USING LIPID VESICLES INCLUDING EXOSOMES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230210902-A1 | SARS-COV-2-SPECIFIC T CELLS | NATIONAL INSTITUTES OF HEALTH | 2023-07-06 | — | — | US | disclosed |
| EP-4149496-A1 | SARS-COV-2-SPECIFIC T CELLS | Board of Regents, The University of Texas System (US) | 2023-03-22 | — | — | EP | disclosed |
| EP-4126035-A1 | COMPOSITIONS AND METHODS FOR TARGETING CORONAVIRUS USING LIPID VESICLES INCLUDING EXOSOMES | Board of Regents, The University of Texas System (US) | 2023-02-08 | — | — | EP | disclosed |
| US-20220401479-A1 | LARGE-SCALE COMBINED CAR TRANSDUCTION AND CRISPR GENE EDITING OF T CELLS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2022-12-22 | — | — | US | disclosed |
| US-20070293872-A1 | Ocular Drainage Device | MINU, L.L.C. (US) | 2007-12-20 | — | — | US | disclosed |
| WO-2007115376-A1 | ANTI-ANGIOGENIC AGENTS AND METHODS OF THEIR USE | THE UNIVERSITY OF WESTERN AUSTRALIA (AU) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007038453-A2 | USE OF AN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AGENT TO AMELIORATE INFLAMMATION | ADVANCED OCULAR SYSTEMS LIMITED (AU) | 2007-04-05 | — | — | WO | disclosed |
| US-20070071754-A1 | Method to ameliorate inflammation | MINU, LLC | 2007-03-29 | — | — | US | disclosed |
| US-20070072933-A1 | Delivery of an ocular agent | MINU, LLC | 2007-03-29 | — | — | US | disclosed |
| US-20070071756-A1 | Delivery of an agent to ameliorate inflammation | MINU, LLC | 2007-03-29 | — | — | US | disclosed |
| US-20070031471-A1 | Uses of Amniotic Membranes as Biocompatible Devices | MINU, L.L.C. (US) | 2007-02-08 | — | — | US | disclosed |